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Aim: To analyze the accuracy of diagnosis in a population receiving inhaled therapies due to 
respiratory diseases in a primary care setting.
Method: Noninterventional, multicenter, cross-sectional, observational epidemiologic study 
methodology.
Results: A total of 9752 subjects were evaluated. Of these, 4188 (42.9%) patients were 
  diagnosed with asthma, 4175 (42.8%) with chronic obstructive pulmonary disease (COPD), 
and 1389 had a diagnosis of disease of unknown origin. Of those over the age of 40 years, 4079 
(50.9%) had COPD and 2877 (35.9%) had asthma. Sixty percent of the subjects were men, and 
the proportion of men was higher in patients with COPD (83.2%) than in the group with asthma 
(39.8%, P , 0.0001). Of subjects with COPD, 17.3% had mild, 55.3% had moderate, 24.1% 
had severe, and 3.2% had very severe disease. With regard to the level of severity of asthma, 
34.9% of subjects had intermittent, 34.6% had mild persistent, 27.1% had moderate persistent, 
and 3.5% had severe persistent disease. Only 13.9% of patients in the COPD group had all the 
characteristics of COPD based on the Global Initiative for Chronic Obstructive Lung Disease 
criteria and an absence of the characteristics of asthma.
Conclusions: The majority of patients receiving inhaled therapy in primary care did not have 
an accurate diagnosis according to current international guidelines for COPD and asthma. More 
initiatives for improving diagnostic accuracy in respiratory diseases must be implemented in 
primary care.
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Introduction
Respiratory diseases that progress with obstruction of the respiratory tract are very 
prevalent in the community, giving rise to high health care costs. Asthma and chronic 
obstructive pulmonary disease (COPD) stand out in this group of diseases.
Asthma may affect individuals of any age. Although its prevalence varies from 
one country to another, it is estimated to be 1%–18% on a global level. The results 
from the European Community Respiratory Health Survey indicated that asthma rates 
in Spain are low, although they vary according to regions, with a range between 5% 
and 14.5%.1 COPD mainly affects individuals over the age of 40 years. The Spanish 
IBERPOC study suggests that the prevalence of COPD in Spain is 9.1% for patients 
who are 40–69 years of age.2
In countries where patient monitoring is coordinated in primary care, as in Spain, 
an analysis of the situation at this level would provide valuable information on the 
impact that COPD and asthma has on the community and on the treatment needs of International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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the population, regardless of the level of care, where the 
diagnosis is made, or whether there is additional follow-up 
in specialized health care services.
Asthma and COPD have certain similarities. Therefore, 
it is not easy to differentiate between them, especially in 
patients over the age of 40 years or those with spirometry 
that does not show complete reversibility of obstruction. 
Various studies have confirmed in both pathologies that there 
are problems of under-diagnosis, wrong diagnosis, a high 
percentage of patients with overlapping symptoms, and little 
observance of good clinical practice guidelines. The knowl-
edge that the general population has about these diseases may 
also have an influence on health care needs and thus, on the 
diagnosis of one disease or the other. A population-based 
survey has shown a greater proportion of people who knew 
about asthma compared with those who knew about COPD 
(30% versus 8.6%, respectively).3
Given that both diseases are clearly different in their 
pathophysiology, different approaches to their treatment must 
be taken, despite certain features they may have in common. 
The excellent clinical response to inhaled corticosteroids 
(ICs) in asthma, and these agents are considered to be first-
line treatment. In the case of COPD, the response to ICs is 
variable and when these are used, they are always a second-
line treatment in combination with a bronchodilator.4–6 When 
more selective drugs are used (eg, leukotriene inhibitors), 
this difference becomes especially relevant. From a clinical 
point of view, the differential diagnosis between the two 
diseases holds interest beyond the purely theoretic, because 
their pathophysiologic basis, clinical evolution, and thera-
peutic strategies are different.7,8 Furthermore, knowing the 
characteristics of both disease processes in our population 
allows for the development of health strategies targeted to 
the needs of patients.
The objectives of this study were to analyze the accuracy 
of diagnosis in a population receiving inhaled therapies due to 
respiratory diseases in the primary care setting, to determine 
the diagnoses established by primary care physicians in this 
population, and to identify patient characteristics.
Materials and methods
study design
An observational, cross-sectional, multicenter, noninter-
ventional, epidemiologic study was performed in patients 
attending primary health care facilities and being treated 
with inhalers. The investigators’ decisions regarding health 
care or the medical treatment most appropriate for the 
patient did not have any influence on the methods used in 
the study. Because this was a cross-sectional, observational 
study, all data required for the assessment of endpoints 
included in the protocol were recorded during a single visit. 
The subjects participated in the study from 14 May 2008 
to 26 November 2008. The project was approved by the 
Clinical Research Ethics Committee of the University 
Hospital of Guadalajara. All patients signed an informed 
consent form.
The study participants were selected by consecutively 
taking the first seven patients in a given practice population 
who were over the age of 18 years, met all the selection 
criteria (Table 1), and had attended a primary health care 
consultation. A total of 9931 subjects were recruited for the 
study by 1449 investigators.
Data collection was carried out using a   standardized 
  questionnaire including both clinical and functional 
  variables. Bronchodilator tests were considered to be 
  positive when baseline FEV1 increased by more than 200 mL 
and 12%. Diagnosis was left to the investigator’s judgment 
according to his/her routine clinical practice assuming that, 
  according to published data, most of the patients would be 
diagnosed with COPD or asthma. Subsequently, the reliabil-
ity of the   diagnosis of asthma or COPD was assessed using 
GINA (Global Initiative for Asthma)9 and GOLD (Global 
  Initiative for Chronic Obstructive Lung Disease)10 criteria, 
  respectively, as a reference in order to support one or other 
of the   diagnoses, based on exposure to environmental risk 
factors, age and characteristics of symptom onset, previous 
history of atopy or asthma, and findings from spirometry. 
Bronchodilator tests were not used as a differentiation 
criterion, except in cases where a complete resolution of 
obstruction was confirmed. Patients not assigned by the 
  physicians to asthma or COPD diagnosis groups were 
included for analysis purposes as a third group named 
“  disease of unknown origin”.
Table 1 selection criteria
Inclusion criteria
 •  Patients aged $18 years
 •    Patients in treatment with an inhaled drug (bronchodilator or inhaled 
steroids)
 •  Patients who have signed the informed consent
exclusion criteria
 •    Patients who have previously experienced an exacerbation of their 
pulmonary disease within the last four weeks prior to the inclusion 
visit
 •  Patients whose clinical history data were not available
 •    Patients having, at the time the study was performed, any serious 
physical or mental impedimentInternational Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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statistical analysis
It was initially agreed that a percentage of patients having a 
characteristic with a 95% confidence interval (CI) would be 
obtained for estimates of qualitative variables. A percentage of 
50% was assumed in all the qualitative variables, because this 
percentage ensures a greater sample size, and therefore a better 
estimate. According to these considerations, the CI of 95% 
observed using normal distribution for large samples, at least 
9500 individuals would need to be assessed in order to obtain 
a precision error of less than 1%. Finally, with 9752 evaluable 
subjects, the CI of 95% using a normal   distribution for large 
samples obtained a precision error not greater than 1%.
The population used for the statistical analysis included 
patients who met all the selection criteria. If the case report 
forms were missing any information (not included by the 
  investigator), the results were calculated using data from indi-
viduals who had these data. Therefore, the sample size varied 
for the different variables due to the amount of missing data. For 
each variable, the total number of subjects evaluated is supe-
rior to the sum of the number of evaluated patients diagnosed 
with asthma, COPD, or disease of unknown origin because 98 
of 147 patients were diagnosed as having asthma and COPD 
together, so were not included in the analysis, and in other cases 
the investigators did not specify the diagnosis on the form.
Descriptive statistics of all the variables, including 
central tendency means and dispersion for all the quantita-
tive variables, as well as relative and absolute frequencies 
for the qualitative variables, were performed with CIs of 
95% in both cases. The distribution of the quantitative 
variables was studied and its adjustment to the Gaussian 
distribution was assessed using the Kolmogorov-Smirnov 
test. In order to compare independent data from more than 
two groups (among the different analysis groups), a   one-way 
analysis of variance (ANOVA) was performed for the 
quantitative variables, as well as a Chi-square test for the 
qualitative   variables. Statistical tests were performed with a 
5%   significance level and were bilateral. The SAS® version 
8.2 statistical package was used for all statistical analyses.
Results
A total of 9931 individuals were included in the study, and 
179 (1.8%) were excluded because they did not meet the 
selection criteria, ie, 9752 (98.2%) subjects were assessed and 
classified according to the type of diagnosis made by their 
physician. Of these, 4188 (42.9%) patients were diagnosed 
with asthma, 4175 (42.8%) with COPD, and 1389 had 
alternative diagnoses. One hundred and forty-seven patients 
were excluded because of a mixed diagnosis of asthma and 
COPD or because the investigators did not specify a diagnosis 
on the form. Excluding these patients, 1242 (12.8%) were 
classified as having disease of unknown origin. Of patients 
over the age of 40 years, 4079 (50.9%) were diagnosed with 
COPD, 2877 (35.9%) with asthma, and 13% had alternative 
diagnoses.
Table 2 describes the demographic data and body mass 
index (BMI) of patients included in the study. Sixty percent 
were men, who comprised a higher percentage of patients 
diagnosed with COPD (83.2%) than those with asthma 
(39.8%; P , 0.001). The mean age (standard deviation 
[SD]) of patients with COPD was 67.2 (11.0), which was 
older than the age of asthma patients, ie, 50.1 (17.0) years 
(P , 0.0001). The average BMI was 27.2 (4.3) kg/m2. Higher 
rates of excess weight and obesity were observed in patients 
diagnosed with COPD, and the percentage of patients who 
were underweight was low in all the groups.
As it can be seen in Table 3, 37.8% of the population had 
never smoked, 37.2% were ex-smokers, and 24.9% were 
current smokers (P , 0.0001). The average number of years 
smoking was 28.2 (13.9). However, this was slightly higher 
at 22.6 (12.5) years in patients diagnosed with COPD, and 
notably lower at 18.2 (10.6) years in patients with an asthma 
diagnosis (P , 0.0001).
Using the British Medical Research Council dyspnea scale, 
66.0% of the subjects had disease of unknown origin, 90.6% had 
COPD, and 65.1% had asthma and basal dyspnea (Figure 1).
Only 4379 (44.9%) patients had spirometry performed, 
either prior to or during the study. Mean values (CI 95%) 
of the FEV1/FVC postbronchodilator ratio were 75.8% 
(73.7–77.9), 66.5% (65.3–67.6), and 76.9% (75.7–78.1) in 
the disease of unknown origin, COPD, and asthma diagnosis 
groups, respectively (P , 0.0001). In these groups, FEV1 
as a percentage of predicted was 77.4% (75.7–79.2), 60.6% 
(59.7–66.4), and 77.8% (76.8–78.7). For the bronchodilator 
test, the average absolute change (CI 95%) in FEV1 (L) was 
0.2 (0.2–0.3) in the group with disease of unknown origin, 
0.2 (0.2–0.3) in the group with COPD, and 0.3 (0.3– 0.4) in 
the group with asthma (P , 0.0052). The change in percent-
age values, compared with baseline, was 10.2% (7.5–12.9), 
15.9% (10.8–21.1), and 15.9% (13.2–18.1) in the three 
groups, respectively (P = 0.24).
According to the GOLD guidelines, as can be seen in 
Figure 2, 17.3% of the subjects with a COPD diagnosis (based 
on spirometry data, n = 1878) had mild, 55.3% had moderate, 
24.1% had severe, and 3.2% had very severe disease. With 
respect to severity levels in patients with asthma, according 
to GINA guidelines, 34.9% had intermittent, 34.6% had International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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persistent mild, 27.1% had moderate persistent, and 3.5% 
had severe persistent disease (Figure 3).
Table 4 shows the subjects’ personal history of atopy, 
  urticaria, eczema, and rhinitis. These diseases were more 
  prevalent in asthma patients than in COPD patients (P , 0.0001). 
The proportion of subjects with allergies was also higher in sub-
jects with asthma (41.4%) than in those with COPD (11.3%, 
P , 0.0001). A previous history of atopy and asthma symptoms 
were also more frequent in subjects with asthma (P , 0.0001); 
81.7% had experienced episodes of wheezing, and this was 
lower in patients with COPD (76.2%) than in patients with 
asthma (89.7%, P , 0.0001); 48.8% had suffered chronic 
  expectoration, being slightly lower in patients with asthma 
(21.9%) and higher in patients with COPD (79.4%, P , 0.0001). 
However, apart from the normalization of post-bronchodilator 
pulmonary function, no other clinical parameter allowed for the 
establishment of a precise cut-off point in order to distinguish 
asthma from COPD. Therefore, only 13.9% of the patients in 
the COPD group showed, simultaneously, all the typical charac-
teristics of COPD disease based on GOLD criteria and absence 
of typical asthma characteristics. In total, 36.7% of patients had 
previously been admitted to hospital at least once, and most of 
them were from the COPD group rather than the asthma group 
(51.4% and 27%, respectively, P , 0.0001).
Table 2 Characteristics of the study population. The total number of subjects evaluated is greater than the sum of patients diagnosed 
with asthma, COPD, or disease of unknown origin, because of lack of inclusion of patients with both asthma and COPD and those for 
whom the investigators did not specify a diagnosis on the form are not included
Total Unknown origin COPD Asthma P-value
gender
 n  
  Male 
  Female
9,480 
5692 (60.0%) 
3788 (40.0%)
1,209 
615 (51.0%) 
593 (49.0%)
4,068 
3385 (63.2%) 
683 (16.8%)
4,068 
1618 (39.8%) 
2450 (60.2%)
,0.0001
Age (years)
 n  
  Average (sD) 
  95% CI of average 
  Median (P25/P75)
9,711 
58.3 (16.6) 
(53.0; 58.7) 
61.0 (47.0/71.0)
1,238 
54.6 (16.7) 
(53.7; 55.5) 
56.0 (42.0/68.0)
4,157 
67.2 (11.0) 
(66.9; 67.5) 
69.0 (60.0/75.0)
4,174 
50,5 (17,0) 
(50.0; 51.0) 
50.0 (38.0/64.0)
,0.0001
BMI (kg/m1)
 n  
  Average (sD) 
  95% CI of average 
  Median (P25/P75)
9,465 
27.2 (4.3) 
(27.1; 27.3) 
26.8 (24.3/29.5)
1,212 
26.5 (4.1) 
(26.3; 26.8) 
26.2 (23.8/28.7)
4,051 
28.1 (4.2) 
(27.9; 28.2) 
27.7 (25.4/30.4)
4,064 
26.5 (4.4) 
(26.4; 26.7) 
26.1 (23.6/28.9)
,0.0001
BMI classification according to the WHO*
 n  
  Underweight 
  normal weight 
  Overweight 
  Chronic obesity 
  Premorbid obesity 
  Morbid obesity
9.465 
108 (1.1%) 
2794 (29.5%) 
4450 (47.0%) 
1670 (17.6%) 
345 (3.7%) 
98 (1.0%)
1,212 
12 (1.0%) 
440 (36.3%) 
547 (45.1%) 
174 (14.4%) 
30 (2.5%) 
9 (0.7%)
4,051 
36 (0.9%) 
826 (20.4%) 
2054 (50.7%) 
904 (22.3%) 
83 (4.5%) 
48 (1.2%)
4,064 
58 (1.4%) 
1486 (36.6%) 
1783 (43.9%) 
568 (14.0%) 
130 (3.2%) 
39 (1.0%)
,0.0001
*Underweight (≤18.5); normal weight (18.5–25); Overweight or class I obesity (25–30); Chronic obesity or class II obesity (30–35); Premorbid or class III obesity (35–40); 
Morbid obesity or class IV obesity (≥40).
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; BMI, body mass index; SD, standard deviation; WHO, World Health Organization.
Table 3 smoking among the different groups
Total Unknown origin COPD Asthma P-value
smoking
 n 9,711 1,238 4,159 4,173 ,0.0001
  never 3,675 (37.8%) 576 (46.5%) 607 (14.6%) 2,436 (58.4%)
  ex-smoker 3,617 (37.2%) 321 (25.9%) 2,332 (56.1%) 921 (22.1%)
  Active 2,419 (24.9%) 341 (27.5%) 1,220 (29.3%) 816 (19.6%)
 n 4,883 531 2,935 1,344 ,0.0001
  Average (sD) 31.5 (24.5) 24.5 (20.0) 39.5 (24.7) 17.0 (16.1)
  95% CI of average (30.8; 32.2) (22.8; 26.2) (38.6; 40.4) (16.1; 17.8)
  Median (P25/P75) 27.0 (15.0/42.0) 20.0 (10.0/32.0) 35.0 (22.5/50.0) 12.0 (5.3/22.5)
Abbreviations: CI, confidence interval; COPD, chronic obstructive pulmonary disease; SD, standard deviation.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Table 5 shows active treatment at the time of   evaluation. 
Given the study protocol, patients who were only being treated 
with antileukotrienes, theophylline, or   maintenance oral 
  corticosteroids were not assessed. In 46.5% of the   subjects with 
disease of unknown origin, 62.1% of patients with COPD, and 
60.9% of the patients with asthma,   treatment comprised a fixed 
combination of long-acting beta2-  adrenergic agonists and ICs, 
while 42.1% of subjects with disease of unknown origin, 43.7% 
of those with COPD, and 48.7% of those with asthma were 
taking short-acting beta2-adrenergic agents. A lower percentage 
of patients was receiving   mucolytic medication (being higher 
in COPD patients), ICs, and long-acting anticholinergics. With 
regard to inhaled and noninhaled treatments, 28.9% and 28.3% 
of COPD patients were receiving two and three treatments, 
respectively, and 37.1% and 22.3% of those with asthma were 
taking two and three treatments, respectively (Table 6).
Total Unknown origin COPD Asthma
50%
45%
40%
35%
30%
25%
20%
15%
10%
5%
0%
No dyspnea Mild Moderate Severe Very severe
Figure 1 severity of dyspnea in patients with diseases of unknown origin, chronic obstructive pulmonary disease, and asthma.
Abbreviation: COPD, chronic obstructive pulmonary disease.
60%
50%
40%
0%
30%
10%
20%
Mild Moderate Severe Very severe
Figure 2 Chronic obstructive pulmonary disease severity according to Global Initiative for Chronic Obstructive Lung Disease classification.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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Discussion
The results of this study provide clinical information 
  regarding patients receiving inhaled therapies in primary care. 
At the same time we were able to analyze the main limitations 
for these diagnoses when we used international guidelines 
for the more frequent respiratory diseases seen in primary 
care, ie, asthma and COPD. The main difference between 
the asthmatic patients and those diagnosed with COPD is 
that there was a greater predominance of women, younger 
patients, lower baseline dyspnea, a different distribution of 
disease severity, and more symptoms of atopy, allergy, and 
rhinitis documented in asthma patients. These profiles meet 
the clinical characteristics for asthma and COPD according 
to the GINA and GOLD guidelines, respectively. However, 
because there is no gold standard that allows for confirma-
tion of a correct diagnosis (unless obstruction of airflow is 
completely reversed), the proportion of wrong diagnoses 
could not be assessed for each disease group, because many 
patients do not fit a typical asthma or COPD profile.
The difficulty in making a differential diagnosis between 
the two diseases is already recognized as a significant clinical 
problem. In fact, in 1995, the American Thoracic Society stated 
that “it may be impossible to differentiate patients with asthma 
whose airflow obstruction does not remit   completely from 
patients with chronic bronchitis and emphysema with a par-
tially reversible obstruction and   bronchial hyperreactivity”.11
Cigarette smoking can be a confounding factor when 
attempting to diagnose asthma or COPD. In our study, the 
percentages of current smokers and ex-smokers among 
patients diagnosed with COPD and asthma were 85.4% and 
41.7%, respectively. In another study recently performed in 
our community using a very large sample of women with a 
COPD diagnosis, 57.3% of patients stated that they had never 
smoked. This raises some doubts about the correct diagnosis 
of COPD and suggests the existence of other predisposing 
factors.12
One limitation of our study is that the diagnosis was based 
solely on the judgment of the physician caring for the patient. 
Therefore, reliability cannot be determined.   Difficulty in 
making a diagnosis of asthma or COPD was more common in 
patients over the age of 40 years with chronic airflow obstruc-
tion. In these patients, differentiation between the two diseases 
must be made on clinical grounds, including all possible infor-
mation in order to establish a diagnosis. In fact, although our 
series had more characteristics associated with asthma, such 
characteristics, in isolation, are not enough to differentiate 
accurately between the two diseases. In the population over 
the age of 40 years, 50.9% had a   diagnosis of COPD, but only 
13.9% of those patients had all the typical characteristics of 
COPD based on GOLD criteria and absence of all asthma 
characteristics at the same time. These data   suggest that there 
could be a significant percentage of patients with an incorrect 
or unclear diagnosis. Tinkelman et al   analyzed this problem in 
a population over the age of 40 years who were looked after in 
the primary care setting and had a prior diagnosis of COPD or 
were receiving treatment for COPD. Among subjects for whom 
COPD was “confirmed” through spirometry, 37.9% had a prior 
diagnosis of asthma and had no data showing chronic bronchitis 
or emphysema.13 However, this approach may not be valid, 
because a COPD diagnosis is assumed to be correct simply 
35%
30%
25%
20%
0%
15%
5%
10%
Intermittent Persistently
mild
Persistently
moderate
Persistently
severe
Figure 3 Asthma severity according to Global Initiative for Asthma classification.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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when chronic air flow obstruction, defined as FEV1/FVC ,70% 
is recorded. In other cases, even when introduction of multiple 
variables into the analysis (clinical, functional, and analytic 
variables) was attempted in the development of questionnaires, 
a precise diagnosis cannot be established in approximately 20% 
of patients. These patients frequently have a typical history of 
COPD and atopy or are ex-smokers with clinical characteristics 
of asthma.14–16 These data are similar to those presented in the 
National Health and Nutrition Examination Survey III17 where 
the degree of overlap ranged from 17% to 19.1%.
Table 4 Personal and family histories of asthma characteristics in the study population
Personal history Total Unknown origin COPD Asthma P-value
Atopy
 n 9,412 1,207 4,088 4,001 ,0.0001
  no 7,784 (82.7%) 1,043 (86.4%) 3,888 (95.1%) 2,787 (69.7%)
  Yes 1,628 (17.3%) 164 (13.6%) 200 (4.9%) 1,214 (30.3%)
Urticaria
 n 9,346 1,206 4,081 3,955 ,0.0001
  no 7,914 (84.7%) 1,047 (86.8%) 3,801 (93.1%) 2,983 (75.4%)
  Yes 1,432 (15.3%) 159 (13.2%) 280 (6.9%) 972 (24.6%)
eczema
 n 9,204 1,203 4,030 3,869 ,0.0001
  no 7,264 (78.9%) 936 (77.8%) 3,523 (87.4%) 2,729 (70.5%)
  Yes 1,940 (21.1%) 267 (22.2%) 507 (12.6%) 1,140 (29.5%)
rhinitis
 n 9,415 1,212 4,024 4,057 ,0.0001
  no 5,691 (60.4%) 776 (64.0%) 3,390 (84.2%) 1,475 (36.4%)
  Yes 3,724 (39.6%) 436 (36.0%) 634 (15.8%) 2,582 (63.6%)
Known allergies
 n 9,302 1,179 3,996 4,013 ,0.0001
  no 6,972 (75,0%) 1,009 (85.6%) 3,545 (88.7%) 2,350 (58.6%)
  Yes 2,330 (25,0%) 170 (14.4%) 451 (11.3%) 1,663 (41.4%)
Family history
Atopy
 n 9,244 1,189 4,045 3,897 ,0.0001
  no 8,018 (86.7%) 1,057 (88.9%) 3,874 (95.8%) 3,014 (77.3%)
  Yes 1,226 (13.3%) 132 (11.1%) 171 (4.2%) 883 (22.7%)
Asthma
 n 9,207 1,168 3,951 3,973 ,0.0001
  no 6,424 (69.8%) 920 (78.8%) 3,434 (86.9%) 2,013 (50.7%)
  Yes 2,783 (30.2%) 248 (21.2%) 517 (13.1%) 1,960 (49.3%)
Abbreviation: COPD, chronic obstructive pulmonary disease.
Table 5 Treatment list (active at the time of assessment)
Total Unknown origin COPD Asthma
N = 9,752 N = 1,242 N = 4,175 N = 4,188
N (%) N (%) N (%) N (%)
Fixed combination LABA/IC 5,794 (59.4%) 576 (46.6%) 2,592 (62.1%) 2,550 (60.9%)
short-acting beta-2 adrenergic agents 4,437 (45.5%) 523 (42.1%) 1,823 (43.7%) 2,038 (48.7%)
Mucolytic medication*** 2,755 (28.3%) 319 (25.7%) 1,691 (40.5%) 705 (16.8%)
Inhaled corticoids (IC) 2,402 (24.63%) 269 (21.7%) 1,016 (24.3%) 1,071 (25.6%)
Long-acting anticholinergics 2,258 (23.2%) 141 (11.4%) 1,693 (40.6%) 374 (8.9%)
Long-acting beta-2 adrenergic 
agonists (LABA)
1,939 (19.9%) 200 (16.1%) 1,006 (24.1%) 700 (16.7%)
Antileukotrienes** 1,455 (14.9%) 107 (8.6%) 328 (7.9%) 987 (23.6%)
short-acting anticholinergics 907 (9.3%) 83 (6.7%) 565 (13.5%) 245 (5.9%)
Theophylline*** 758 (7.8%) 43 (3.5%) 532 (12.7%) 168 (4.0%)
Maintentance oral corticoids** 642 (6.6%) 37 (3.0%) 420 (10.1%) 172 (4.1%)
Other non-inhaled agents 361 (3.7%) 37 (3.0%) 121 (2.9%) 200 (4.8%)
Other inhaled agents 1 (0.0%) 1 (0.1%) 0 (0.0%) 0 (0.0%)
Notes: ***Certain patients were taking more than one treatment; **Maintentance oral corticoids refers to the use of this drug at the moment of the study.
Abbreviations: COPD, chronic obstructive pulmonary disease; IC, inhaled corticosteroids, LABA, long-acting beta2-adrenergic agonists.International Journal of Chronic Obstructive Pulmonary Disease 2010:5 submit your manuscript | www.dovepress.com
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In view of the lack of good clinical and/or analytic 
  parameters that make it possible to differentiate between these 
two diseases, it has become common to use the   bronchodilator 
test, both in daily clinical practice and in clinical trials. 
  Therefore, many authors interpret a positive bronchodilator 
test as being synonymous with asthma. However, Anthonisen 
et al18 demonstrated that a large number of patients diagnosed 
with COPD showed a positive response if the test is repeated, 
and more than 60% show at least one positive response when 
a series of consecutive bronchodilator tests are performed.
Recently, the UPLIFT (Understanding Potential Long-
term Impacts on Function with Tiotropium) study has con-
firmed these results, ie, more than 50% of COPD patients 
had a positive bronchodilator response.19 Even though the 
GOLD guidelines state that a positive response occurs with 
an increase of 200 mL or a 12% increase in FEV1 compared 
with baseline, this criterion varies notably in different series 
and clinical guides, with ranges varying from 10% to 20%. 
In practice, none of these rates show acceptable levels of 
reproducibility, and the bronchodilator test cannot be seen as 
a dichotomous variable confirming or denying a diagnosis. 
That is the reason why the bronchodilator test distinguishes 
asthma from COPD so poorly. Thus, unless the disappear-
ance of the obstruction is confirmed, this test should not 
be used to make a differential diagnosis between the two 
diseases.208–22 In spite of the frequency with which a limit of 
15% has been indicated in order to determine a diagnosis of 
asthma or “asthmatic bronchitis”, this is the average value 
of functional improvement obtained by Anthonisen in a 
group of COPD patients, in which an asthma diagnosis was 
considered to be an exclusion criterion.18 It should be noted 
that the 15% increase in FEV1 obtained in the bronchodilator 
test was documented in both the asthma and COPD groups, 
with no significant differences between them.
Although the asthma prevalence was similar to that of 
COPD in this large series of patients, there are significant 
differences in the severity of both diseases, in that 69.5% of 
asthma patients had intermittent or persistent mild disease, 
whereas 82% of COPD patients had moderate or severe 
  disease. Even though the criteria used to assess the severity of 
both diseases are different, these data can justify the existence 
of a greater basal clinical repercussion, with dyspnea levels 
being significantly higher in COPD patients.
Use of spirometry in the primary health care setting remains 
low, and was performed in only 50% of the population treated 
with bronchodilator medication. Another limitation of our study 
is that functional confirmation of COPD was only possible in 
44.9% of the patients who had had spirometry in response to a 
bronchodilator test, which could have influenced our results. In 
a previous study, 26.5% of patients assessed in primary health 
care were diagnosed with COPD although they had had no 
spirometry test or functional report that could aid the diagnosis 
and establish disease severity. Our results are very similar to 
those of other epidemiologic studies. Women and nonsmoking 
patients were less likely to have spirometry done. However, 
multivariate analysis did not show any effect of gender or 
smoking on whether or not spirometry was performed.23
The pharmacologic prescription pattern was similar 
between the two diseases, with the exception of a greater use of 
tiotropium and mucolytic agents in COPD and a greater use of 
leukotriene antagonists in asthma. Given that   bronchodilators 
and ICs are the most common treatments for asthma and 
COPD, not surprisingly the prescription profile is similar 
in both cases. Unfortunately, it was not possible to obtain 
information regarding the doses used or the consumption 
per year. This information would have helped to determine 
the consumption profile of these drugs in both disease groups 
in order to determine if they were temporary or permanent 
prescriptions. The greater use of mucolytic agents, tiotropium, 
and theophylline in COPD patients is also not surprising. 
  However, the significant consumption of leukotriene antago-
nists in COPD patients is notable, given their lack of efficacy 
in this disease. These data are consistent with the findings of 
other observational studies performed in this setting.24–26
Table 6 number of inhaled and noninhaled treatments that each patient received
Total Unknown origin COPD Asthma P-value
number of inhaled and non-inhaled treatments
n 9,676 1,223 4,159 4,153 ,0.0001
1 2,409 (24.9%) 526 (43.2%) 662 (15.9%) 1,199 (28.9%)
2 3,211 (33.2%) 415 (33.9%) 1,200 (28.8%) 1,540 (37.1%)
3 2,313 (23.9%) 177 (14.5%) 1,176 (28.3%) 925 (22.3%)
4 1,059 (10.9%) 78 (6.4%) 626 (15.1%) 339 (8.2%)
5 464 (4.3%) 17 (1.4%) 332 (8.0%) 106 (2.6%)
+5 220 (2.3%) 8 (0.7%) 163 (3.9%) 44 (1.1%)
Abbreviation: COPD, chronic obstructive pulmonary disease.International Journal of COPD
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In conclusion, the majority of patients in our study who 
were receiving inhaled therapy in primary care did not have 
an accurate diagnosis according to current international 
guidelines for COPD or asthma. The percentage of patients 
diagnosed with asthma or COPD was similar, although 
there were relevant differences in gender, age, and clinical 
  characteristics. More initiatives for improving diagnosis 
accuracy in respiratory diseases must be implemented in 
primary care, and focusing on use of spirometry.   Improving 
the differential diagnosis in primary care will improve the 
management of these common respiratory diseases and 
  ultimately improve the health care of affected patients.
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